Drug Trial Radar · NCT06539507
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
76
Actual
Start
Sep 26, 2024
Primary completion
Dec 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- BioCryst PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
Conditions
- Netherton Syndrome
Interventions
BCX17725Drug
BCX17725 for injection
PlaceboDrug
Placebo for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: From screening through EOS (ie, through Day 78 in Parts 1 and 3, and Day 106 in Part 2)
- Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12 (Part 4)Time frame: From baseline to Week 12
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Stanford University School of Medicine
Palo Alto, California
Therapeutics Clinical Research
San Diego, California
Yale Center for Clinical Investigation
New Haven, Connecticut
Northwestern Dermatology CTU
Chicago, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Westmead Hospital - Department of Dermatology
Sydney, New South Wales, Australia
Nucleus Network
Brisbane, Queensland, Australia
Veracity Clinical Research
Brisbane, Queensland, Australia
Hôpital Saint-Louis
Paris, France
Universitätsklinikum Heidelberg
Heidelberg, Germany
Maastricht Universitair Medisch Centrum (MUMC+)
Maastricht, Netherlands
Erasmus Universitair Medisch Centrum (EMC)
Rotterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.